Research map: Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area

Back to the article

Papers in this map

  1. Atopic dermatitis endotypes and implications for targeted therapeutics · Tali Czarnowicki · 2019 · 636 citations · Cited by this paper
  2. Consensus Recommendations for Management of Darier Disease: A Practical Approach · 2026 · Related
  3. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis · Jonathan I. Silverberg · 2023 · 343 citations · Cited by this paper
  4. Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy · 2026 · Related
  5. Atopic dermatitis · Emma Guttman‐Yassky · 2025 · 308 citations · Cited by this paper
  6. Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension · 2026 · Related
  7. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review · Nicoleta Neagu · 2022 · 75 citations · Cited by this paper
  8. Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment · 2026 · Related
  9. A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis · Ida Vittrup · 2023 · 64 citations · Cited by this paper
  10. JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study · 2026 · Related
  11. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial · Lisa A. Beck · 2022 · 57 citations · Cited by this paper
  12. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo · 2026 · Related
  13. Updated Review on Treatment of Atopic Dermatitis · José Carlos Armario-Hita · 2023 · 48 citations · Cited by this paper
  14. Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study · 2026 · Related
  15. Tralokinumab in the treatment of resistant atopic dermatitis: An open‐label, retrospective case series study · Elena Pezzolo · 2022 · 30 citations · Cited by this paper
  16. Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study · 2026 · Related
  17. Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients · Andrea Chiricozzi · 2021 · 26 citations · Cited by this paper
  18. Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region · 2026 · Related
  19. Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action · Christopher G. Bunick · 2025 · 19 citations · Cited by this paper
  20. Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival · 2026 · Related
  21. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects · Miguel Antonio Lasheras‐Pérez · 2023 · 15 citations · Cited by this paper
  22. Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study · Gianluca Avallone · 2025 · 14 citations · Cited by this paper
  23. Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis · Jenny E. Murase · 2025 · 9 citations · Cited by this paper
  24. Head and neck dermatitis: a variant of atopic dermatitis · Leszek Blicharz · 2025 · 8 citations · Cited by this paper
  25. Tralokinumab efficacy in a case of dupilumab‐resistant severe atopic dermatitis complicated by eczema herpeticum · Maria Efenesia Baffa · 2023 · 7 citations · Cited by this paper
  26. Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study · Jonathan I. Silverberg · 2026 · 6 citations · Cited by this paper
  27. Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study · Gianluca Avallone · 2025 · 4 citations · Cited by this paper
  28. Effectiveness of Anti‐ IL ‐13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48‐Week Outcomes by Lebrikizumab and Tralokinumab · Mizuki Shiba · 2026 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)